MPI for Heart and Lung Research
You are here: MPI HLR Home > Home > Pharmacology

2016: Dieter-Klaus-Preis (ShengPeng Wang)
for his work on the identification of a new endothelial mechanisms of blood pressure control.

2016: Hermann-Rein-Preis (Boris Srilic)
for the discovery of a new mechanism mediating tumor cell metastasis.

2016: Rudi-Busse-Promotionspreis (Cong Tang)
for his thesis on loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes.

2015: Novartis Award for Therapy-relevant research (Nina Wettschureck)
for work on the role of GPCR HCA2 in mediating the beneficial effects of DMF in neuroinflammation (with H. Schwaninger, Lübeck).

2013: Rudolf-Buchheim Award (Dagmar Schumacher)
for her work on platelet-derived nucleotides in tumor cell transendothelial migration and metastsis.

2012: Galenus-von-Pergamon Award (Thomas Worzfeld)
for his work on plexin B1 on ErbB-2-expressing tumors.

2011: Otto-Hahn-Medaille (Kashan Ahmed)
for the discovery of a new receptor activated by lactate which plays an important role in the regulation of adipocyte lipolysis.

2011: Rudolf-Buchheim Award (Antonia Sassmann)
for her work on beta cell regulation through G-protein-mediated signaling.

Prof. Dr. Nina Wettschureck

Max Planck Institute for Heart and Lung Research
Department of Pharmacology
Ludwigstr. 43
61231 Bad Nauheim

Phone: +49 (0)6032 705 1214
Fax: +49 (0)6032 705 1204
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Curriculum Vitae

Since 2012                    Professor for Molecular Pharmacology, University of Frankfurt / Main

Since 2009                    Group Leader, Max-Planck-Institute for Heart and Lung Research Bad Nauheim.

2007                             "Habilitation" for Pharmacology and Toxicology, University of Heidelberg

2000 - 2009                   Postdoctoral Research Fellow, Institute of Pharmacology, University of Heidelberg

1998 – 2000                  Postdoctoral Research Fellow, Institute of Pharmacology, FU Berlin

1996 – 1998                  Dept. of Internal Medicine V, University of Heidelberg

1990 – 1996                  Studies of Medicine, M.D. degree, University of Frankfurt / Main, Germany


G-protein signaling group (Wettschureck group)

Group leader: Nina Wettschureck

Postdocs: Malarvizhi Gurusamy

PhD students: Jingchen Shao, Tianpeng Wang, Jeonghyeon Kwon, Niharika Shiva, Hilal Taskiran

Technical assistant: Martina Finkbeiner

Our group studies all aspects of cell communication in the vessel wall, for example the regulation of leukocyte/endothelial interactions, the interplay between endothelial cells and smooth muscle cells, and the communication between vascular cells and stromal/parenchymal cells. Most of our projects focus on the large family of G-protein-coupled receptors (GPCRs), which mediate the intracellular effects of numerous hormones, neurotransmitters, or local mediators. In the past, we identified new functions for GPCRs and their effector families G12/13 and Gq/11 in the cardiovascular, endocrine, and immune system (for example Herroeder et al., Immunity 2009; Sassmann et al., J Clin Invest 2010; Takefuji et al., Circulation 2012; Takefuji et al., J Exp Med 2013; Sivaraj et al., Dev Cell 2013; Chen et al., J Clin Invest 2014; Kaur et al., Circ Res 2016). More recently, we focus on orphan GPCRs, i.e., GPCRs with yet unknown endogenous ligand and function. To better understand the biological function of these enigmatic GPCRs, we performed single-cell expression analyses in primary murine vascular and immune cells (Kaur et al., Nat Commun 2017; Tischner et al., JCI Insight 2017) and identified rare cell populations with specific GPCR repertoires. Based on these data, we are currently analyzing the function of orphan GPCRs in specialized subpopulations of smooth muscle (Carvalho et al., Circulation 2020), endothelial cells and immune cells (Gurusamy et al., Nat Commun 2021, accepted). Other projects address the role of angiocrine factors in cardiac remodeling or the regulation of leukocyte/endothelial interactions.

Wettschureck group projects illustrated

Overview of topics addressed by the G-protein signaling group.


Selected references

Gurusamy M, Tischner D, Shao J, Klatt S, Zukunft S, Bonnavion R, Günther S, Siebenbrodt K, Kestner RI, Kuhlmann T, Fleming I, Offermanns S, Wettschureck N (2021): G-protein-coupled receptor P2Y10 mediates facilitation of chemokine-induced CD4 T cell migration through autocrine/paracrine mediators. Nat Commun, 12(1):6798.

Carvalho J, Chennupati R, Li R, Günther S, Kaur H, Zhao W, Tonack S, Kurz M, Mößlein N, Bünemann M, Offermanns S, Wettschureck N (2020). Orphan G-protein-coupled receptor GPRC5B controls smooth muscle contractility and differentiation by inhibiting prostacyclin receptor signaling. Circulation 141(14):1168-83.

Tischner D, Grimm M, Kaur H, Staudenraus D, Carvalho J, Looso M, Günther S, Wanke F, Moos S, Siller N, Breuer J, Schwab N, Zipp F, Waisman A, Kurschus FC, Offermanns S, Wettschureck N (2017): Single-cell profiling reveals GPCR heterogeneity and functional patterning during neuroinflammation. JCI Insight 3;2(15), doi: 10.1172.

Kaur H, Carvalho J, Looso M, Singh P, Chennupati R, Preussner J, Günther S, Albarrán-Juárez J, Tischner D, Classen S, Offermanns S, Wettschureck N (2017): Single-cell profiling reveals heterogeneity and functional patterning of GPCR expression in the vascular system. Nat Commun 8:15700; DOI: 10.1038.

Kaur H, Takefuji M, Ngai C, Carvalho J, Bayer J, Wietelmann A, Poetsch A, Holper S, Conway SJ, Mollmann H, Looso M, Troidl C, Offermanns S, Wettschureck N (2016): Targeted Ablation of Periostin-Expressing Activated Fibroblasts Prevents Adverse Cardiac Remodeling in Mice. Circ Res. 118:1906-17.

Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, Kohl J, Offermanns S, Wettschureck N*, and Schwaninger M* (2014): Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest 124:2188-92. (*contributed equally)

Sivaraj KK, Takefuji M, Schmidt I, Adams RH, Offermanns S, and Wettschureck N (2013): G13 controls angiogenesis through regulation of VEGFR-2 expression. Dev Cell 25:427-34.

Takefuji M, Kruger M, Sivaraj KK, Kaibuchi K, Offermanns S, and Wettschureck N (2013): RhoGEF12 controls cardiac remodeling by integrating G protein- and integrin-dependent signaling cascades. J Exp Med 210:665-73.

Takefuji M, Wirth A, Lukasova M, Takefuji S, Boettger T, Braun T, Althoff T, Offermanns S, and Wettschureck N (2012): G13-mediated signaling pathway is required for pressure overload-induced cardiac remodeling and heart failure. Circulation 126:1972-82.

Sassmann A, Gier B, Grone HJ, Drews G, Offermanns S, and Wettschureck N (2010): The Gq/G11-mediated signaling pathway is critical for autocrine potentiation of insulin secretion in mice. J Clin Invest 120:2184-93.

Herroeder S, Reichardt P, Sassmann A, Zimmermann B, Jaeneke D, Hoeckner J, Hollmann MW, Fischer KD, Vogt S, Grosse R, Hogg N, Gunzer M, Offermanns S, Wettschureck N (2009): Guanine nucleotide-binding proteins of the G12 family shape immune functions by controlling CD4+ T cell adhesiveness and motility. Immunity 30:708-20.





Die nachstehenden Informationen enthalten die gesetzlich vorgesehenen Pflichtangaben zur Anbieterkennzeichnung sowie wichtige rechtliche Hinweise zur Internetpräsenz des Max-Planck-Instituts für Herz- und Lungenforschung (


Anbieter dieser Internetpräsenz ist im Rechtssinne die
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.


zur Förderung der Wissenschaften e.V.
Hofgartenstraße 8
80539 München
Telefon: +49 (89) 2108 - 0


Die Max-Planck-Gesellschaft ist im Vereinsregister des Amtsgerichts Berlin-Charlottenburg unter der Registernummer VR 13378 B eingetragen.


Die Max-Planck-Gesellschaft wird gesetzlich vertreten durch den Vereinsvorstand, und dieser wiederum durch den Präsidenten, Prof. Dr. Martin Stratmann, und den Generalsekretär, Herrn Rüdiger Willems.


Die Umsatzsteueridentifikationsnummer der Max-Planck-Gesellschaft lautet:
DE 129517720

Redaktionsverantwortlich für die Internetpräsenz der Abteilung II: Pharmakologie des Max-Planck-Instituts für Herz- und Lungenforschung i. S. d. P.

Frau Svea Hümmer (Sekretariat Abt. II: Pharmakologie)


Rechtliche Hinweise zur Organisationsform

Die Max-Planck-Gesellschaft ist eine gemeinnützige Forschungseinrichtung, die in der Rechtsform eines eingetragenen Vereins organisiert ist. Die Institute und Einrichtungen der Max-Planck-Gesellschaft sind organisatorisch weitgehend selbständig und haben in der Regel keine eigene Rechtspersönlichkeit.

Visuelles Erscheinungsbild

Konzept und Gestaltung: EDVAS

Programmierung: Alexander Schmidt auf Joomla!



Prof. Dr. Stefan Offermanns
This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone:  +49 (0)6032 705 1201

Offermanns group

  • G-protein-coupled receptors - read more
  • Signalling and mechanotransduction in the cardiovascular system - read more
  • Metabolic signaling in obesity and diabetes - read more
  • Tumor cell metastasis - read more
  • Semaphorin-plexin signaling - read more


Wettschureck group